415 related articles for article (PubMed ID: 22204764)
1. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Mujtaba T; Dou QP
Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
[TBL] [Abstract][Full Text] [Related]
3. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
5. From bortezomib to other inhibitors of the proteasome and beyond.
Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ubiquitin-proteasome pathway in cancer therapy.
Ishii Y; Waxman S; Germain D
Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
[TBL] [Abstract][Full Text] [Related]
7. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
8. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.
Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J
Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428
[TBL] [Abstract][Full Text] [Related]
11. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
12. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathways: targeting proteasomal protein degradation in cancer.
Molineaux SM
Clin Cancer Res; 2012 Jan; 18(1):15-20. PubMed ID: 22019514
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
15. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin proteasome pathway from bench to bedside.
Orlowski RZ
Hematology Am Soc Hematol Educ Program; 2005; ():220-5. PubMed ID: 16304384
[TBL] [Abstract][Full Text] [Related]
17. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
O'Connor OA
Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]